Harmony Q3: WAKIX Revenue $268.9M, Guidance Reiterated, BP-205 MAD Data Positive
HRMY sits 40% above its 52-week low of $25.902.
Summary
Harmony reported Q3 WAKIX net revenue of $268.9 million, up 12%, and reiterated $1.0-$1.04 billion full-year guidance, while disclosing favorable BP-205 multiple-ascending dose data and a January 26, 2027 preliminary injunction hearing in its pitolisant patent fight.
Key Events · Earnings and Guidance · HRMY
-
Q3 WAKIX Revenue Up 12%
WAKIX net revenue was $268.9 million versus $239.5 million a year earlier, with 400 net patient adds bringing average patients to 9,350.
-
Guidance Reiterated at $1.0B-$1.04B
Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion was reaffirmed after nine-month revenue of $745.6 million.
-
Earnings Dip on Milestone Charge
Net income fell to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87, driven by a $25.0 million MSN license milestone charge and new Novitium royalties that lifted cost of product sold to 30% of revenue from 25%.
-
BP-205 MAD Data Support Once-Daily Dosing
In 94 healthy volunteers over 14 days of once-daily dosing, BP-205 showed no serious or severe adverse events, no liver or visual events, and a mean effective half-life of about 29 hours; Phase 1b data are expected in Q1 2027 and Phase 2 studies by mid-2027.
Analysis · HRMY · Life Sciences
The commercial franchise is tracking as expected: WAKIX net revenue rose 12% to $268.9 million, and management reiterated full-year guidance of $1.0 billion to $1.04 billion. Earnings fell to $48.2 million ($0.81 per diluted share) from $50.9 million ($0.87), a cost story rather than a demand problem, driven by a $25.0 million MSN license milestone charge and new Novitium royalties. More consequential is the BP-205 multiple-ascending dose data: 14 days of once-daily dosing produced no serious or severe adverse events, no liver or visual events, and a ~29-hour effective half-life that supports once-daily use, keeping Phase 1b data on track for Q1 2027 and Phase 2 starts by mid-2027. With $1,051.6 million of cash and investments, the company is funding this pipeline itself. The patent calendar is the main swing factor: closing arguments in the AET ANDA case were held October 22, 2026, and a preliminary injunction hearing on the amorphous '920 patent is set for January 26, 2027, with a ruling expected by February 14, 2027, when the 30-month stay expires.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRMY was trading at $36.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.90 to $43.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.